Investment thesis: As mentioned in our previous articles, Eonia Research focuses heavily on analyzing the underlying science of biotechs. After a prolonged search, we have found an intriguing biotech operating in the chimeric antigen receptor T-cell (CAR-T) space, Autolus therapeutics (AUTL). We believe Autolus' CD19-targeted asset (AUTO1) will achieve best-in-class status among CD19-targeted therapies for adult relapsed/refractory acute lymphoblastic leukemia (r/r ALL). The company's relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) asset (AUTO3) incorporates both CD19- and CD22-targeting with excellent efficacy and toxicity rates. The company has an extensive pipeline of "next-generation" CAR-T